Iwander, Thanks for posting this discussion. Watching it was an hour well spent. "The ship has sailed for Fibrate." I think this is extremely important for anyone invested in Amarin. That drug class is probably our biggest competitor. At a point one of the panelists said that EPA was the only proven available option. The success of RESPECT might actually be less important than the failed Fibrate trial. Sleven,
News 
Market Data 
Discover 
